



Bioactive Compounds in Chronic Diseases—2nd Edition

Guest Editor:

Prof. Dr. Vasso Apostolopoulos

Institute for Health and Sport,
Victoria University, Melbourne,
VIC 3011, Australia

Deadline for manuscript
submissions:

20 December 2024

Message from the Guest Editor

Bioactive compounds can be derived from natural products, animal products, and plants, and can be synthetically produced. They have gained widespread attention in recent years as they have shown to be effective in a number of chronic and infectious diseases, such as cancer, cardiovascular disease, diabetes, autoimmune disorders, and infectious diseases. In addition, their use can promote better health. As such, vitamins, minerals, herbal, polyphenols, pre- and pro-biotics, natural products, nutritional therapies, and cannabis therapies have been shown to boost the immune system, consequently helping to manage and treat disease. This Special Issue will focus on natural and bioactive treatments used to overcome or manage chronic and infectious diseases, including in vitro, animal in vivo, and human clinical studies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)